Introduction
Somatostatins (SSTs) are regulatory peptides involved in inhibition of an umber of endocrine and exocrine secretion functions through somatostatin receptors, which are Gprotein-coupled receptors (GPCRs).
[1] SSTsr egulate the secretion of factors such as insulin and growth hormone. All five SST receptor subtypes (SSTRs) are able to down-regulate cell proliferation,b ut they vary in an umber of other functions such as the regulation of ion channels.
[1a] Thus, their effects on cell proliferation and apoptosis are of interest for developing nonpeptidic agonists to enhancet umor growth suppression.
[2] The subtype5, SSTR5, formsaheterodimer with SSTR2 and presents enhanced cell growth inhibition ability. [3] Of the five human (h) SSTRs, hSSTR5 is the only receptor subtypet hat has different affinities for the two endogenousl igands SST-14 and SST-28, whicha re cyclic peptides with 14 and 28 residues,r espectively. [4] SSTR5 has ah igher affinity for SST-28, which is shown to suppress glucagon-like peptide-1( GLP-1)s ecretion much more effectively than SST-14.
[5] Therefore, hSSTR5 antagonists are potentially useful for the treatment of diabetes. Indeed, it has been shown that certain nonpeptidic antagonists are able to improveg lucoset olerance in rodentmodels of type 2diabetes. [6] Twop eptide-based somatostatin mimics, octreotide and vapreotide, have been commercialized to treat variousdiseases or conditions such as metastatic carcinoid tumors and esophageal variceal bleeding. In recent years, anumber of small-molecule agonists and antagonists have also been published. [7] However,tothe best of our knowledge,none have passed clinical trials. We expect that designing small-molecule ligands with improved potencya nd greater selectivity would be useful to minimize off-target side effects.
For the rational design of better hSSTR5 ligands, it is essential to know the molecular details of the receptor binding pockets for both the active andi nactive states. Since no experimentals tructures are available for any of the SSTRs, we used computational methods that have provede ffective for other GPCRs. [8] Apart from the biological functions described above, ar ecent study has identified hSSTR5 as one of the most valuable templates for homology modeling of nonorphan and nonolfactoryc lass AG PCRs, whichr epresent the majority of the class AGPCRs(highest sequence identity sum and apercentage of sequences for accurate modelsv alue of 31 %). [9] This has increasedt he significance of obtaining ah SSTR5 structure.
To predictthe 3D structuresofhSSTR5, we developed amodifiedv ersiono fG PCR Ensemble of Structures in Membrane BiLayer Environment (GEnSeMBLE) [10] complete samplingc omputational method, which aims to predictt he 10 to 25 lowerenergy protein structures likely to play ar olei nactivation upon Humans omatostatinr eceptor subtype 5( hSSTR5)r egulates cell proliferation and hormone secretion. However,t he identification of effective therapeutic small-molecule ligandsisi mpeded because experimental structures are not availablef or any SSTR subtypes. Here, we predict the ensembleo fl ow-energy 3D structures of hSSTR5 using am odified GPCR Ensemble of Structures in Membrane BiLayer Environment (GEnSeMBLE) complete sampling computational method. We find that this conformational ensembled isplays most interhelical interactions conserved in class AG protein-coupled receptors (GPCRs) plus seven additional interactions (e.g.,Y 2.43-D3.49, T3.38-S4.53, K5.64-Y3.51) likely conserved among SSTRs. We then predicted the binding sites for as eries of five knowna ntagonists, leadingt op redicted binding energies consistent with experimental resultsr eported in the literature. Molecular dynamics (MD) simulation of 50 ns in explicit water and lipid retained the predicted ligand-bound structure and formed new interaction patterns (e.g. R3.50-T6.34)c onsistentw ith the inactive m-opioid receptor X-ray structure. We suggest more than six mutationsf or experimental validation of our prediction. The final predicted receptor conformationsa nd antagonist binding sites provide valuablei nsights for designing new small-molecule drugstargeting SSTRs.
binding various ligands.G EnSeMBLEh as beens uccessfullya pplied in the predictiono fi nactive-state structures of GPCRs sucha sc annabinoid receptor type 1( CB1), [8a] adenosine A3 receptor( hAA 3 R), [8c] olfactory receptorO R1G1, [8d] bitter taste receptor Ta s2R38,
[8e] the GLP-1r eceptor( GLP1R), [8f] and C-C chemokiner eceptort ype 5( CCR5).
[8g] For CB1 and hAA 3 R, the active states were alsoi dentifieds uccessfully.I np articular for CB1,i th as beend emonstrated thatasingle mutationd ramatically changest he binding sites ot hatt he receptorb ecomesc ompletely inactive,w hereasa nothers ingle mutationm akesi te ssentially completelya ctive. [8a,b] Indeed these same methods successfully predicted whats ingle mutations wouldinterconvert these activities. [8a,b] Herein, we focus on predicting the ensembleo f structures for hSSTR5, using the modified version of the GEnSeMBLE method, and their binding with several known antagonists.
Results and Discussions

GPCR structure predictions
Our predictions of the ensembleo fl ow-energy 3D structures for hSSTR5 followed the general GEnSeM-BLE method, which is described in detail in the Experimental Section. However,w ei ntroduced ah ierarchicalS uperBihelix/SuperComBiHelix sampling procedure (coarse and fine sampling) described below. This new sampling procedure provides am ore systematic means for predicting inactive-state and active-state conformations of the target protein. An overview of the new GEnSeM-BLE procedure applied to hSSTR5 structure prediction is provided in Figure 1 .
To prepare the startings tructures for the GEnSeMBLEp rocedure,wefirstcarried out PredicTM and secondarystructure predictions to determine which residuesa re in the sevenh elical transmembrane domains (TMDs). The PredicTMr esult and the final assignment of eachT MD are showni nF igures S1 and S2 in the SupportingI nformation. Thenw ecarriedo ut multiples equence alignments between hSSTR5 and the GPCRs withX -ray structures available, whichi dentifiedh umann ociceptin receptor (hOPRX),m ouse m-opioid receptor( mOPRM),a nd human kopioid receptor( hOPRK)a st he best candidate templates to model the hSSTR5 structure.T od etermine the shapes of the helices,w eu sedO ptHelixa nd homology modeling. Then, the TMD bundle of hSSTR5 was assembled basedo nt he helixp ositions of eachtemplate. Atotalof15starting structures withdifferent helical shapes and positions were generated.
Among the six parameters (x,y,h,q,f,h)t hat uniquely define the orientation of ar igid TMD,t he hydrophobic center (HPC) residue (h)a nd the Cartesian coordinates (x,y)o ft he HPC, were taken from the template. Amongt he helical tilts and rotations (q,f,h), the helical rotations (h)w ere first sampled using the BiHelix methodw ith as ampling range of Dh from 08 to 3608 and as tep size of 308.
The top 10 structures from the BiHelix step are shown in Ta ble S2 in the Supporting Information, where we see that all 10 structures use homology helix shapes.S ince all three templates were represented in the top 10, we used the rotations for the best candidate from each template in the next step, SuperBiHelix.
SuperBiHelixo ptimizes tilts together with rotations (q,f,h) based on the best structures from BiHelix. For each of these, we first carriedo ut ac oarse sampling step (Dq = 0, AE 158; Df= 0, AE 458, AE 908; Dh = 0, AE 308,o ther selected angles) from angles optimized in BiHelix. This sampled at least (3 53) 7 % 374 billion configurations from which we built and optimized the lowest 2000 7-helix bundles. This was done for all three startingtemplates (mOPRM, hOPRK, hOPRX), with the sampling space for each template summarized in Table S3 in the Supporting Information, and the resulting lowest energy structure for each template shown in Table 1 .
To predict the structures for inactive states,w es elected the lowest energy structure with aT M3-TM6 ionic lock for each template. Then we carried out af iner SuperBiHelix sampling (Dq = 0, AE 158; Df= 0, AE 158, AE 308; Dh = 0, AE 308). This examined (3 53) 7 % 374 billion configurations from which we built and optimized the lowest 2000 7-helix bundles.
As shown in Ta ble 2, the top 10 structures from this fine SuperBiHelix sampling all come from the mOPRM template except for the one ranked 5th, whichi sf rom hOPRK. Thus, we focusedo ns tructures using the mOPRM template in the sub- 6.58 In addition, we found one interaction that we expect to be unique to hSSTR5:
3.30 -S171 4.57 These interactions are shown in Figure 2b .
In order to obtain ad iverse set of low-energy protein structures, we selected two other protein conformations from the 25 lowest energy predicted hSSTR5 structures (listed in Table  S4 in the Supporting Information). Here, we selected the two that have the largest root-mean-square deviation (RMSD) with InactiveConf1 and with each other.T hese two are labeled InactiveConf2 (ranked 7thi nT able 2, and6 th in Ta bleS4i nt he Supporting Information) and InactiveConf3 (ranked 16 th in Ta ble S4 in the Supporting Information).
To obtain structures that might be candidates for active states (with TM6 well separated from TM3), we carriedo ut af iner sampling starting from the best structures from the coarse sampling that satisfy specific structural criterion,w hich is described below.T he resulting optimal active-state structures are namedA ctiveConf1 and ActiveConf2.
To distinguish potentialactive-state from inactive-state structures, we defined R 36 ,t he distance between the intracellular ends of TM3 andT M6, to be the shortest distance between the backbonea toms of the four residues at the intracellular ends of TM3 and TM6. We selected the lowest energystructure with an R 36 value 4 larger than the R 36 value of 7.18 f rom the inactive-state structure InactiveConf1. The active-inactive R 36 value difference of 4was chosen because the X-ray struc- www.chemmedchem.org tures for both human b 2 -adrenergic receptor (hb 2 AR) and bovine rhodopsin display this feature. Then we carriedo ut af iner sampling of (q, f, h)o nt his selected structure to obtain the first putativelya ctive conformation, ActiveConf1. Substituting the TM6 shapei nt his startings tructure with the TM6 from the homology model with active hb 2 AR X-ray structure followed by finer sampling gives the second putatively active conformation ActiveConf2 (for details, see the Supporting Information). These will be described and used in as ubsequent paper that validates this new hierarchical sampling method and predicts active structures for hSSTR5. As ummary of all structures used in the following antagonist binding study is in Ta ble 3.
Antagonist binding
To validate the structures predicted for the hSSTR5 receptor, we predicted the binding site and energy for five known small-molecule antagonists to the five predicted protein structures (InactiveConf1,2,3;A ctiveConf1,2). The antagonists chosen for the docking were selected from as eries of benzoxazole piperidines screened by Martin and co-workers, [7c] which exhibit aw ide range of binding affinities while retaining the same structurals caffold of the ligand ( Figure 3 ). The molecules are labeled "Mx", with "x" preserving the numbering scheme from Ref.
[7c].W es elected M38, M40, M42, M59, M60 based www.chemmedchem.org on their experimentally determined binding affinities (K i )f or hSSTR5-M59 is the most potent derivative reported, exhibiting a K i value of 3nm,w hile the other compounds selected exhibit ad iverser ange of binding affinities (from 23 nm to over 1000 nm). The experimental binding affinity,p redicted binding site and energy for the five antagonists chosen are summarized in Ta ble 4. To determine the best pose for each antagonist, we allowed each antagonist to select its preferred conformations out of the docking results to all five predicted protein structures. For each ligand,w es elected the optimal pose for the ligand's preferred binding mode using the best unified-cavity (UCav) energy in comparing the ligand binding. The UCav energy ranked the five ligands as M59 (best) < M60 < M40 < M42 < M38( worst), while the binding energy calculated from DG 1 ÀDG 2 = RTln(K i2 /K i1 )u sing experimental binding constants gives the rank order as M59 < M60 < M38 < M40 < M42. Thus, only M38 is an outlier. The UCav energies range over af actor of nine of the binding energies calculated from the experimental binding constants, which range over 3.57 kcal mol À1 (Table S5 in the Supporting Information).
To further investigate how well our predicted binding energies correlate with the experimental results, we plotted the UCav energy against the negative logarithm of the experimental binding constants (Figure 4 ). This shows that the UCav energies for the optimal poses of the antagonist series correlate with the experimental pK i values with al inear regressioncoefficient of 0.78. This suggests that UCav captures the essential aspects of the relative binding affinities of these antagonists.
We also find that M42 and M60 favor the InactiveConf2 conformation while the other three favor InactiveConf1, which means InactiveConf1 and InactiveConf2 could possibly be two inactive conformations selected by the antagonist series. This suggestst hat the structures of hSSTR5 predicted to be more stable are more likely to be in the inactive state than the less stable ones.
Ta ble 4s hows the ligand interaction diagram (LID) of the best pose for each antagonist. We find that the antagonists predominantly bind with ap ocket defined by TMDs 1-2-3-6-7. In theseb estp oses, all antagonists form as alt bridge between their positivelyc harged piperidine amine group and D119 3.32 .T his aspartic acid on TM3 is conserved in all somatos- www.chemmedchem.org tatin receptors, and mutagenesis studies have shown it is essentiali nS ST binding by forming an electrostatic interaction with ap ositivelyc harged group in SST.
[11] Therefore, our result has further confirmed that D119 3.32 is ac ritical residue in hSSTRs' binding with positivelyc harged ligand groups.
The 3D visualization of these poses is shown in Figure 5 . For M59 andM 60, the ligand position is clearly dominated by the two salt bridges:o ne between the positively charged amine group in the ligand and D119 3.32 ,a nd the other betweent he carboxylic group in the ligand and R39
1.31 .F or M59, we carried out am olecular dynamics (MD) simulation with lipid membrane and aw ater box, and both salt bridges became watermediated after the MD simulation (Section 2.3, below). Unlike D119 3.32 ,R 39 1.31 is not conserved in any hSSTRs. This might explain why the antagonists with polar groups at R 1 or R 2 are extremely selective towards the receptor subtype5.
[7c] Mutating R39 1.31 to an egatively charged residue, an onpolarr esidue, or serine (as in hSSTR1, 2, 3) should be able to test this hypothesis.
Other residues playing an important role in theseh igh-affinity antagonists are polar residues N100 .T his is shown in the pharmacophore mapping in Ta ble 4. The residues interacting with the strongly binding antagonists that are missing in the predicted pose for the nonbinding molecule M42 are F265
6.52 and V290 7.39 .S ince M42 binding is not experimentally detected, we can deduce that F265A and/orV 290A mutations might cause the other antagonists to have ad ecreased affinity towards hSSTR5.
In the predicted binding poses, M38 and M40 both form a p-p stacking interaction between the benzoxazole and W261 6.48 ,b ut both lack the salt bridge with R39
1.31 that is found in the predicted interactions for M59 and M60. Therefore, without the strong electrostatic interaction constraining the ligand position, the weaker p-p interaction becomes ad ominating force of the ligand with the protein. Although M38 does not have as tronger binding in docking than M40 and M42 as predicted, its exposed chlorine group might lower the binding energy once solvation is taken into account.
Apart from the polar groups,t he ligand size also plays ar ole in determining the binding affinities. Figure5a,b shows that the ethoxy group at the R 4 positioni nM 59 prevents the phenylg roup of M59f rom being parallel to the hydrophobic plane of the GPCR as in the M60 pose. The ethoxy group has directedt he M59 phenylh ead to go deeper into the binding pocket and reach more polar and nonpolar residues than M60. This explains why M59 has ah ighera ffinity than M60 for hSSTR5.
Molecular dynamics (MD) simulation
In order to anneal and validate our predicted structure, we carried out a5 0nsM Ds imulationo ft he system with the protein embedded in explicit lipid andwater box starting with the predicted structure of M59-bound InactiveConf1. The RMSD analysis of the trajectory (FiguresS3a nd S4 in the Supporting Information) and fluctuation of R 36 ( Figure 6 ) all suggest that the protein starts to rearrange to ad ifferent state at~41 ns. Such fluctuationsb etween slightly different states of the GPCR along the trajectory are typical in GPCR MD simulations during which water is diffusing into and throughout the protein, modulating varioushydrogen bonds and other interactions.
The hydrogen-bond distances for variousi nteractions along the trajectory are shown in Figures S5-S13 in the Supporting Information. The constancy of these interactions suggest that the overall protein structural features from the region of 33 ns to 41 ns and that of later times are similar with most structural features maintained at the end of 50 ns trajectory.T hus we consider theses tructural features to provide ar eliable representation of the structure. [a] The structure given immediately below the data for each ligand represents the best docked pose ligand interaction diagram (LID). The LIDs were generated using Maestro9.3. [36] The cutoff distance for the residues shown is 4.0 . Hydrophobic interactions:g reen;p olar interactions:b lue;h ydrogen bonds (cutoff distance:2 .5 ): purple arrows; p-p stacking:s traight green lines. ,w hile E243 6.30 forms as alt bridge with R241 6.28 on intracellularl oop 3( IC3). The strong electrostatic interaction with the loop explains the changes in the interatomic distance between R137 3 .50 and E243 6.30 ( Figure S14 in the Supporting Information). D136
3.49 also makes ap olar interaction with R151o n intracellular loop 2( IC2), as shown in Figure 7 . Similarp olar interaction patterns were also observed in the X-ray crystallographic structure of mOPRM,c oupling D164
3.49 andR 165 3.50 in the DRYm otif, and coupling D164 3.49 and R179 on IC2 (Figure 7) . [12] The X-ray structure for hb 2 AR was also found to have analogous patterns (R131 3.50 interacts with D130 3.49 rather than E268 6.30 ,a nd at the same time D130
3.49 has polar interaction with S143 in IC2). [13] The observation that the salt bridge between the intracellular sides of TM3 and TM6 is not formed in the antagonist-bound mOPRM structures supports our observation for the predicted hSSTR5.I na ddition, all other interhelical interactions between side chains found in the apo hSSTR5 structure remaini ntact except for the one involving D119 3.32 because D119 3.32 now engages in interaction with the ligand.A mong the interhelical interactions, K227
5.64 -Y138 3.51 as well as T117 3.30 -S171 4.57 become water-mediated. Figure 6s hows how R 36 changes during the 50 ns MD. It remains in the inactives tate range 87 %o ft he time if we set the inactive/active cut-off to be 8.0 , and 71 %o ft he time if we set the cut-off at 7.5 . We do not find much rotation of TM3 or TM6 relative to each other because the closest backbone atoms between the intracellular side of TM3 and TM6 remain to be between the Ca atoms of R137 3.50 and T247 6.34 81 %o f the time. In addition, the polar interaction between R137 3.50 and T247
6.34 side chains converges to aw ater-mediated hydrogen bond with al ength of~4.5 a lthough the bond length starts from 5.2 a nd quicklyd rops to 1.9 ( Figure S11i nt he Supporting Information). This is an intriguing result because the polar interaction R165 3.50 -T279 6.34 is also found in the antagonist-bound mOPRMX -ray structure, and mutating T279 6.34 to lysine( which mostl ikely breaks this polar interaction) can result in ac onstitutivelya ctivem OPRM receptor. [12] We can therefore infer that the distance between R137 3.50 and T247 6.34 is also critical in determining hSSTR5 activity,a nd mutating T247 6.34 to al ysine residue is likely to give ac onstitutively active hSSTR5. More importantly,s ince both R137
3.50 and T247 6.34 are conserved in all hSSTRs, this hypothesis might be extendable to all hSSTRs.
Analysis of the changes of several protein-ligand interactions during the MD simulation finds that all the proteinligand salt bridges become water-mediated during the dynamics. The salt bridge with D119 3.32 starts to be water-mediated after 4.47 ns, and the one with R39
1.31 starts to be water-mediated after 2.41 ns. Although there are fluctuations during the 50 ns process, from 33 ns to 41 ns, the distance between M59 piperidine amine nitrogena toma nd D119 3.32 carboxylic acid Interactionsb etween important residues on the intracellular end of a) the predicted hSSTR5 structure after 50 ns MD with antagonist M59, and b) mOPRMX-ray structure (Protein Data Bank identifier (PDB ID): 4DKL [12] ). The intracellularl oop 2i sl abeled IC2, and the intracellular loop 3is labeled IC3. fluctuates more vigorously as shown in Figure S13 (see Supporting Information), but this could be because R39
1.31 becomes part of the loop during the dynamics.
Although the protein has as tructural shift right after 41 ns, and the protein can be in different states af ew nanoseconds before and after 41 ns, the two states have many similarantagonist-bound inactive-state characteristics. Therefore, we conclude that the MD simulation retains the character of an antagonist-bound inactive-state structure.
Conclusions
In this study,w ep redicted the ensemble of low-energy structures of hSSTR5 and found plausible binding sites for as eries of antagonists with ac ommon scaffold but ad iverse set of binding constants. We obtained binding energies consistent with the experimental binding constants. Also, these structures exhibit aT M3-TM6 coupling associated with an inactive GPCR. This indicates that predicted structures InactiveConf1 and InactiveConf2 are reasonable hSSTR5 inactive-state structures. In addition, we have identified residues that might be criticali n antagonist binding to hSSTR5, and the results are able to rationalize the order of experimentally determined binding affinities for the five antagonists in the series. Furthermore, the MD simulations show that our antagonist-bound InactiveConf1 structure gains features consistentw ith those experimentally found in closely related GPCRs. We also introduced an approach aimed at systematicallys ampling structures in which TM6 is well separated from TM3 as candidates for active structures in addition to sampling small TM3-TM6s eparation inactive structures.
In conclusion, this study provides structural informationf or the understanding of antagonist binding to hSSTR5 that will likely to be useful in designing new small-molecule antagonists for hSSTR5.W eh ave also provided structuralf eatures that are possible to be extended to other hSSTRs.
Experimental Section
4.1. hSSTR5 structure prediction 4.1.1. PredicTM and secondary structure prediction: determiningthe seven transmembrane domains (TMDs) and any helical extensions beyondthe membrane
We carried out multiple sequence alignments using MAFFT [14] method over all GPCRs having as equence identity greater than 8.8 %(from BLAST) [15] with hSSTR5. Then we used the hydrophobicity values from the White and von Heijne scales [16] to predict the hydrophobicity along the target sequence. Then, we removed noise in the hydrophobicity profile by using the mean hydrophobicity values obtained from averaging windows ranging from seven residues to 21 residues. Regions with ah ydrophobicity value above zero in the final smooth hydrophobicity profile for hSSTR5 ( Figure S1 in the Supporting Information) are defined as "raw" TMDs, leading to exactly seven continuously positive regions expected to correspond to the seven TMDs buried inside the membrane.
The X-ray structures for GPCRs often find helical extensions of the TMDs well beyond what would correspond to the boundary of the membrane (for example, in squid opsin, TM5 and TM6 are helical 25 b eyond the membrane). [17] To identify these helical extensions protruding from the membrane for each helix, we predicted helix propensity using ac ross comparison of consensus results from protein secondary structure prediction servers Porter, [18] SSpro, [19] APSSP2, [20] Jpred, [21] and PSIPRED, [22] all of which predict helical regions using trained neural networks. The raw results are in Figure S2 in the Supporting Information. The final TM helical domains extended from the raw TMDs are denoted as "cap" regions, as indicated in Figure S2 (see Supporting Information).
In PredicTM, we specified the hydrophobic center (HPC) of each helix by one of two criteria: * "Rawmid" takes HPC to be the geometric midpoint of the raw TMD. * "Area" integrates the hydrophobicity over the raw TMD, and takes HPC to be the centroid (half the total area on each side).
The HPCs for all chains were taken to be in the same x-y plane (the midplane of the lipid membrane bilayer).
Template selection
The sequence alignment from PredicTM identified three GPCRs for which X-ray structures were available that had the highest sequence identity over the TM region with hSSTR5: * nociceptin receptor (OPRX HUMAN, hOPRX, 46.79 %) * m-opioid receptor (OPRM MOUSE, mOPRM, 44.62 %) * k-opioid receptor (OPRK HUMAN, hOPRK, 40.33 %)
The next closest GPCR was human CXC chemokine receptor type 4 (CXCR4 HUMAN, hCXCR4, 32.13 %). Thus, for exploring ad iverse set of relatively high sequence identity templates, we used hOPRX (PDB ID:4 EA3 [23] ), mOPRM (PDB ID:4 DKL [12] )a nd hOPRK (PDB ID: 4DJH [24] )a st emplates for our structure predictions. There was no experimental structure available at the time of this study for dopioid receptor (OPRD MOUSE). As ummary of the selected sequence identity comparison is in Ta ble S1 in the Supporting Information.
Predicting the helical shape:OptHelix versus homology modeling
The predicted shape of the TMD is to be used in the future step that determines the tilts and rotations of the TMD. Twom ethods were used to predict the shape of TMDs: * OptHelix generates the helical shape features using energy minimization and molecular dynamics (MD) starting with an a-helix based on the peptide sequence in which residues other than proline, glycine, alanine, serine, and threonine are replaced with alanine. Then after dynamics, the average structure is mutated to the correct sequence. * Homology to the template shape. Here we start with the backbone from the template (usually from an X-ray structure), mutate it to the new sequence, optimize side chains using Side Chain Rotamer Energy Analysis Method (SCREAM), [25] and minimize the TMD.
The detailed description of these two methods can be found in the Supporting Information.
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Assemblingthe bundle
With the shape of each TMD determined, the next step is to assemble the helices into ab undle.
Assuming each TMD to be rigid, six parameters uniquely define the orientation of the TM helices:1 )the HPC residue h (which is taken to be at z = 0s ot hat all TMDs have their HPC on the same plane);2 )&3) the Cartesian coordinates (x,y)o ft he HPC;4 )the inclination angle q of the helical axis relative to the z-axis;5 )the azimuthal angle f;6 )the rotation angle h of the helix around its own helical axis. Except for TM3, we define the reference point for the rotation angle h using the most conserved residue in each TM, which is denoted as n.50 in the Ballesteros numbering scheme. For TM3, we chose 3.32 rather than 3.50 because 3.32 is closer to the center of the helix and is also well conserved.
The hydrophobic centers used in assembling OptHelix helices were obtained using PredicTM (based either on the "area" or "rawmid" criterion as described in Section 4.1.1). The other parameters (x,y,q,f,h)w ere all based on the template protein structure from the Orientations of Proteins in Membranes (OPM) database. [26] We chose helical shapes from both the "minrmsd" (minimum root mean square deviation to the average structure) and "mineng" (minimum energy) criteria (for detailed definitions, see the Supporting Information). Thus, for each of the three template proteins, we generated at otal of four structures based on OptHelix, for at otal of 12. For homology helices, we selected (x,y,h,q,f,h)f rom the template. Now GEnSeMBLE starts with the parameters (x,y,h,q,f,h)o fastarting structure. It then optimizes first h using the BiHelix method, [27] and then optimizes (q, f, h)u sing the SuperBiHelix [28] method, as described in Section 4.1.5. Mutating from the template sequence to the target sequence, hSSTR5 in this case, is likely to make dramatic changes in some of interhelical interactions. Thus, the first step of GEnSeMBLE is to sample all changes in the rotation angles, Dh,f rom 08 to 3608 with as tep size of 308.T his leads to 12 7 % 35 million combinations. Rather than construct 7-helix bundles for all 35 million, the BiHelix method simplifies the problem by considering the 12 pairs of interacting helices independently.T hus for each pair,w ec onsidered 12 2 = 144 cases, for each of which we optimized the residue side chain conformations with SCREAM. This set of 12 144 = 1728 numbers was used to estimate the energies for all 35 million combinations. We then took the lowest 1000 combinations to analyze in the CombiHelix step.
In the CombiHelix step for each of the 1000 combinations from BiHelix, we built the full 7-helix bundle, reoptimized the side chains using SCREAM and minimized for 10 steps. Then the total energies from these 1000 were ordered, and the lowest energy cases were kept for consideration of the optimum tilt angles. We considered four ways to compare the energies: * The total energy of the charged protein (CTotal) * The interhelical energy (CInterH), which neglects the intrahelical energy of each chain * The total energy (NTotal) * The interhelical energy (NInterH)oft he neutralized protein We find that the isolated net charges on aspartic acid, glutamic acid, lysine, and arginine particularly on the external surfaces of the protein can cause what we consider to be artifacts in the energetics. Thus we neutralize these charged residues by adding or subtracting ap roton for surface residues and transferring ap roton within each salt bridge. This leads to two sets of energy:N To tal and NInterH.
From many previous studies, we found that the most reliable scoring criterion for identifying the best structures is to combine these four criteria. Thus each conformation was ranked by "E CNti ", which is the average energy of CTotal, CInterH, NTotal, and NInterH. This averaging method puts more weight on interhelical energies than on intrahelical energies. We have validated that for the known X-ray structures, and this procedure correctly identifies the known X-ray rotation angles as the lowest energy structures. [28] 4.1.5.2. Selectingthe optimum helical tilts (q,f f)and rotations (h)using the SuperBiHelix method Our previous studies showed that, starting with the X-ray structure of one GPCR, we could not match the structure of adifferent GPCR without allowing both the helix rotations and helix tilts to change. To make this search practical, we developed the SuperBiHelix method. [28] Starting with the optimum rotation angles from BiHelix, we first carried out ac oarse sampling step (Dq = 0, AE 158; Df= 0, AE 458, AE 908; Dh = 0, AE 308,s elected angles from BiHelix), which involved more than (3 53) 7 %374 billion configurations. The selected angles of Dh apart from 0a nd AE 308 were those appearing more than twice in top 20 structures of the BiHelix result or appearing in top 3, and are shown in Ta ble S3 in the Supporting Information. The energies for all these configurations were estimated using the BiHelix energies but combined into three groups of quad helices as explained by Bray and coworkers. [28] For the top 2000 combinations of tilts and rotations, we built the 7-helix bundles, optimized the side chains and selected the best case based on the energy ranking.
The subsequent finer SuperBiHelix sampling was based on the selected coarse sampling resulting structures, and the sampling range was Dq = 0, AE 158; Df= 0, AE 158, AE 308; Dh = 0, AE 308. Again, the top 2000 combinations were built into 7-helix bundles.
Dockingofa ntagonists
Ligandpreparation
Our strategy for docking (GenDock) is to select ad iverse set of low-energy ligand conformations for each of which we sample ac omplete set of poses. The initial structure of M59 was built based on the X-ray crystallographic structure of am olecule, M48, which has the same benzoxazole piperidine scaffold.
[7c] To decrease the torsional sampling space, we replaced the ethoxy groups in M59 with methoxy groups for the sampling of conformations. This modified molecule is labeled "M59m". Then ac onformational search was done on M59m using the MacroModel 9.7 module [29] in Maestro 9.1. [30] This conformational search involved six rotatable bonds other than those in the piperidine ring. It used aM onte Carlo Multiple Minimum (MCMM) method [31] with the OPLS 2005 force field. [32] The energy window for the generated structure to be kept was set to be 10.04 kcal mol
À1
.T he conformational search was done with the RMSD cutoff of 2.0 . Subsequently,aclustering of the resulting conformations was performed to identify 12 distinct ligand conformations expected to represent the entire set of www.chemmedchem.org 705 conformations generated from the previous step. The clustering criterion is RMSD of 0.5 .
Then we added the terminal methyl groups back to M59m, rotated the OÀCb ond in the ethoxy groups and generated five possible M59 conformations from each M59m conformation. Similarly,w e modified the M59 structures to obtain structures for the other antagonists.
The charge distribution was obtained by the Mulliken population analysis using B3LYP/6-311G** in Jaguar 7.6. [33] 4.2.2. Scanning the complete set of poses for each ligand conformation
The DarwinDock procedure modifies the receptor structure to replace the six types of hydrophobic residues by alanine, and then samples the complete set of poses (~50 000) for regions that could potentially bind al igand. To do this sampling, the potential binding region is filled by SphGen with "spheres" having 2 overlaps with each other and the spheres classified into "boxes" of 10 sides. Boxes containing 75 or more spheres were kept. For docking purpose, we have discarded all spheres except for those that are in the extracellular half of the GPCR TMDs and are not potentially in contact with the membrane lipids (i.e. are in the interior of the GPCR helix bundle).
Docking procedure
For each of the five protein structures and for each ligand conformation, we generated 200 000 poses without energy evaluation aiming at providing ac omplete set of poses. The poses were clustered into~7300 Voronoi families based on RMSD and the binding energy of the family head evaluated. Then for the top 10 %o ff amilies, we evaluated the energy for all children. Then we selected the top 50 based on each three energy scores:polar energy,hydrophobic energy,a nd total energy.T hen for these 150, we dealanized (mutating alanine back to the original hydrophobic residues) and optimized the side chains using SCREAM. Then the protein-ligand complexes (poses) were subject to minimization. Then as imulated annealing was performed on the lowest energy 15 complexes before another minimization was done. All final poses were scored together by unified-cavity (UCav) energy.The UCav energy of aparticular pose is defined as the binding energy of the ligand of this pose and the union of the binding pocket (cavity) of all poses. A "cavity" is defined as residues within 5of the ligand of ap articular pose.
Molecular dynamics (MD)
Loop building
The protein structure prediction and ligand docking described in Section 4.1 and 4.2 were all done on TM bundles without the connecting intracellular (IC) and extracellular (EC) loops. In order to do MD simulations on the best protein-ligand complexes from previous steps (best M59-InactiveConf1 pose), we constructed the loops connecting the TMDs as follows. The IC2, IC3 and EC3 loops have high sequence identity with the template mOPRM, so these loops were constructed using homology methods, mutating the aligned residues in mOPRM according to the hSSTR5 sequence. Loop EC2 has ad isulfide bond with TM3, which is similar to that in mOPRM. The disulfide bond induces loop EC2 in mOPRM to have ah airpin structure, but hSSTR5 has fewer residues in the hairpin.
Thus, we constructed EC2 of hSSTR5 by cutting off the extra residues and mutating the remaining residues for EC2 of mOPRM. The remaining loops, IC1 and EC1 were built with aM onte Carlo technique that grows geometrically allowed loop structures from the two fixed TM ends. Then we added the Cterminus of hSSTR5 up to the Cterminus of Helix 8( C320) by attaching Helix 8o ft he template after aligning their NPxxY motifs followed by mutating to hSSTR5. In addition, we added the Nterminus from residue 36-38. Minimization of 500 steps was then carried out on the final structure while keeping the TMDs fixed, and then the whole structure was subjected to minimization of 500 steps.
Building the lipid/water environment
Using Visual Molecular Dynamics (VMD), [34] this final protein structure from the step above was inserted into a7575lipid bilayer structure. The system was then placed into aw ater box with at otal of~8300 water molecules in the 15 a nd 25 t hick space on the extracellular and intracellular sides of the lipid bilayer.Inaddition, Na + and Cl À ions were placed into the system for ap hysiological NaCl concentration and an eutral system. The final system had atotal of 43 104 atoms.
MD simulation
We used the CHARMM22 force field for the protein, and the CHARMM27 force field for lipids and water as implemented in NAMD 2.6. [35] The conjugate gradient method was used in minimization. The NosØ-Hoover Langevin piston pressure control was used in the dynamics. The MD protocol had four steps: 1) With the protein and ligand fixed, the lipids and water molecules in the system were minimized for 5000 steps using the conjugate gradient method. 2) With the protein and ligand fixed, the lipids and water molecules were equilibrated at 310 Ka nd 1atm for 1.5 ns using the NPT ensemble. This allowed the water molecules to defuse into the ligand-protein system to modify the interactions.
3) The whole system (43 104 atoms) was then minimized for 5000 steps using the conjugate gradient method. 4) The whole system was heated from 0K to 310 Ki n~30 ps and then equilibrated for 50 ns using the NPT ensemble.
